Nurix advances bexobrutideg trials, reports $87.2M quarterly loss

Nurix reported a Q1 net loss of $87.2M for the quarter ended Feb 28, 2026 (vs. $56.4M a year ago) and revenue fell to $6.3M from $18.5M (-~66%). Cash and securities totaled $540.7M as of Feb 28, 2026 (down from $592.9M), and the company reported a strong current ratio of 7.02. Operationally, Nurix is advancing bexobrutideg—enrolling a Phase 2 DAYBreak CLL trial, planning a Phase 3 confirmatory trial by mid-2026 and a Phase 1 tablet study supporting IND filings—while analysts raised price targets to $32–$35 and the company amended an equity distribution agreement allowing up to $413.65M in common stock sales. These results present a tradeoff between widening near-term losses and tangible pipeline/strategic progress (and potential dilution risk).

Analysis

The competitive landscape for BTK degraders is entering a phase where speed of enrollment and regulatory pathway choices will disproportionately determine value transfer between small developers and big-pharma partners. A rapid Phase 2 enrollment and a clean single-arm efficacy signal will compress uncertainty and materially increase M&A/partnership optionality within 12–24 months; conversely, slower enrollment or marginal efficacy will lengthen cash runway pressure and make financing the dominant value lever.

Operational execution — CMC scale-up and comparator selection — is an underappreciated second-order determinant of valuation here. Contract manufacturing bottlenecks or a messy comparator campaign can delay registrational starts by quarters, converting a clinical-read catalyst into a funding event that forces dilution and resets multiples. Watch partner pipelines: parallel progress by strategic partners can both validate the mechanism and crowd out licensing upside if they internalize commercialization.

Near-term market moves will be driven less by headline analyst upgrades and more by three binary events: (1) confirmation of registrational trial initiation cadence, (2) AACR data pulses that change perceived ORR/DOR, and (3) any equity raise execution that meaningfully expands float. Each has different horizons (weeks-to-months for AACR/readouts, midyear for registrational start, immediate for financing) and distinct mechanical impacts on implied volatility and share supply.

Key Decisions for Investors

• NRIX — Tactical long with protection: Buy shares as a base (small size) and purchase 6–12 month protective puts to cap downside around a financing or adverse readout. R/R: asymmetric upside if registrational momentum accelerates (2x+ rerating within 12 months) vs downside limited to put cost plus share move.
• NRIX — Volatility/catalyst play: Buy a calendar or long strangle ahead of AACR and the midyear registrational-start window (expiry covering both events). Risk limited to premium; payoff if data or trial-start announcement drives a >30% move in either direction.
• NRIX — Contingent short: Prepare a short or buy deep-in-the-money puts to deploy only if a large equity offering is executed at or below the current share price (initiate within 24–72 hours of deal pricing). This isolates dilution-driven downside where fundamentals are unchanged but supply overwhelms demand.
• SNY — Strategic hedge: Small long in the partner (SNY) to capture upside from successful degrader validation while lowering single-stock exposure to NRIX binary outcomes. Timeframe 12–24 months; use position sizing to maintain low correlation to the NRIX tactical book.